CN108576792A - 一种复方壳寡糖调理癌症的膳食及其制备方法 - Google Patents
一种复方壳寡糖调理癌症的膳食及其制备方法 Download PDFInfo
- Publication number
- CN108576792A CN108576792A CN201810341127.8A CN201810341127A CN108576792A CN 108576792 A CN108576792 A CN 108576792A CN 201810341127 A CN201810341127 A CN 201810341127A CN 108576792 A CN108576792 A CN 108576792A
- Authority
- CN
- China
- Prior art keywords
- diet
- polysaccharide
- compound
- chitosan oligosaccharide
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 45
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 title claims abstract description 38
- 201000011510 cancer Diseases 0.000 title claims abstract description 36
- 235000005911 diet Nutrition 0.000 title claims abstract description 36
- 230000037213 diet Effects 0.000 title claims abstract description 36
- 150000001875 compounds Chemical class 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 230000003750 conditioning effect Effects 0.000 title claims description 11
- 150000004676 glycans Chemical class 0.000 claims abstract description 60
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 59
- 239000005017 polysaccharide Substances 0.000 claims abstract description 59
- 241000233866 Fungi Species 0.000 claims abstract description 46
- 239000000843 powder Substances 0.000 claims abstract description 26
- 241001145025 Saussurea involucrata Species 0.000 claims abstract description 25
- 238000000855 fermentation Methods 0.000 claims abstract description 23
- 230000004151 fermentation Effects 0.000 claims abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 16
- 229940107666 astragalus root Drugs 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 8
- 238000009835 boiling Methods 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 240000001307 Myosotis scorpioides Species 0.000 claims description 14
- 229910052711 selenium Inorganic materials 0.000 claims description 13
- 239000011669 selenium Substances 0.000 claims description 13
- 229940091258 selenium supplement Drugs 0.000 claims description 13
- 229920001661 Chitosan Polymers 0.000 claims description 12
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 11
- 235000019441 ethanol Nutrition 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 9
- 238000003809 water extraction Methods 0.000 claims description 9
- 241001061264 Astragalus Species 0.000 claims description 8
- 235000006533 astragalus Nutrition 0.000 claims description 8
- 241000190633 Cordyceps Species 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- 210000001519 tissue Anatomy 0.000 claims description 7
- 241001327634 Agaricus blazei Species 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 5
- 210000004233 talus Anatomy 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 241000143060 Americamysis bahia Species 0.000 claims description 3
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 claims description 3
- 108010059892 Cellulase Proteins 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- -1 alcohol alcohol Small-molecule Chemical class 0.000 claims description 3
- 229940106157 cellulase Drugs 0.000 claims description 3
- 230000006196 deacetylation Effects 0.000 claims description 3
- 238000003381 deacetylation reaction Methods 0.000 claims description 3
- 230000032459 dedifferentiation Effects 0.000 claims description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 238000002663 nebulization Methods 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 238000012372 quality testing Methods 0.000 claims description 3
- 229960001471 sodium selenite Drugs 0.000 claims description 3
- 239000011781 sodium selenite Substances 0.000 claims description 3
- 235000015921 sodium selenite Nutrition 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 229920002527 Glycogen Polymers 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 238000000034 method Methods 0.000 abstract description 9
- 230000015556 catabolic process Effects 0.000 abstract description 6
- 238000006731 degradation reaction Methods 0.000 abstract description 6
- 230000000259 anti-tumor effect Effects 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 4
- 239000000470 constituent Substances 0.000 abstract description 4
- 230000000242 pagocytic effect Effects 0.000 abstract description 4
- 210000004881 tumor cell Anatomy 0.000 abstract description 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 3
- 241000411851 herbal medicine Species 0.000 abstract description 3
- 210000004698 lymphocyte Anatomy 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 abstract description 3
- 230000009466 transformation Effects 0.000 abstract description 3
- 230000004936 stimulating effect Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 11
- 210000003734 kidney Anatomy 0.000 description 8
- 235000013305 food Nutrition 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 241001248610 Ophiocordyceps sinensis Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 241001264174 Cordyceps militaris Species 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- 229920000018 Callose Polymers 0.000 description 2
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 2
- 241000382353 Pupa Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 2
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 231100000206 health hazard Toxicity 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241001480006 Clavicipitaceae Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241001504592 Trachurus trachurus Species 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- VNYMQKINNCZIQN-UHFFFAOYSA-M [O-][Se](O)=O.[Na+].[SeH2] Chemical compound [O-][Se](O)=O.[Na+].[SeH2] VNYMQKINNCZIQN-UHFFFAOYSA-M 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000003356 anti-rheumatic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000037111 immune power Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种复方壳寡糖调理癌症的膳食及其制备方法,所述膳食的原料质量百分比为壳寡糖粉2~4%、复方真菌多糖43%~53%、雪莲培养物30%~40%、黄芪提取物3%~25%;膳食的制备方法为分别制备壳寡糖粉、复方真菌多糖、雪莲培养物、黄芪提取物并按其质量比称取混合即可;膳食的原料不用传统的粉碎和熬制方法,全部采用现代中药发酵提取技术,降解原料中的有害物质,高效获取中药的活性成分并且应用了多种活性多糖,活性多糖可以刺激免疫活性,能增强网状内皮系统吞噬肿瘤细胞的作用,促进淋巴细胞转化,激活T细胞和B细胞,并促进抗体的形成,从而在一定程度上具有抗肿瘤的活性。
Description
技术领域
本发明涉及食品领域,尤其涉及一种复方壳寡糖调理癌症的膳食及其制备方法。
背景技术
癌症,是人类健康的顶级杀手,一旦患上癌症,就会毁灭一个人或一家人的美好生活。据中国信息产业网调查,近几年,我国的恶性肿瘤整体发病率不断上升,在十种恶性肿瘤中,肺癌、乳腺癌、结直肠癌、胃癌、肝癌和食管癌名列前茅。2011年为250.28/10万。到2014年,上升至276.16/10万,且还有不断恶化之中。2017年2月国家癌症中心发布了中国最新癌症报告显示:在中国,每年新发癌症病例达429万,也就是说全国每天约1万人确诊癌症,每1分钟约7人确诊患癌。若中国人均预期寿命是85岁,那么每个人的累计患癌风险高达36%。在世界范围内,大约22%的新增癌症病例和27%的癌症死亡发生在中国。由此可见,对于癌症的防治,已成为全民大健康的沉重负担,面临各种挑战。
现有癌症治疗方案有很多选择,不但设备先进,而且技术高超,有手术切除治疗术、化学药物治疗术、放射线照射术,还有靶向治疗术、基因治疗术、高温治疗术、冷冻治疗术、激光治疗术以及新发展的细胞免疫术等等,但普遍采用的方法还是手术和放化疗。
这些方法见效快,对挽救生命发挥了重要作用。但是这些方法也容易产生毒副作用,特别是采用放化疗方式,会导致患者免疫力下降,诱发新的病症,基本属于抢救过程。同时,患者治疗费用昂贵,平均要用掉一生中70%的积蓄;另一方面,现在的治疗方式缺少二线治疗方案,肿瘤是一种易复发的疾病,复发病人意味着之前的治疗方案不理想,越治免疫力越低,越治生存时间越短;虽然可以采用中草药进行二线治疗,但是采用没有发酵提取的中草药治疗仍存在大量毒副作用,并且效果较差。
发明内容
本发明目的是解决上述问题,发明一种见效快、无毒副作用的复方壳寡糖调理癌症的膳食及其制备方法。
为了实现上述目的,本发明的技术方案是:
一种复方壳寡糖调理癌症的膳食,所述膳食的原料质量百分比为壳寡糖粉2~4%、复方真菌多糖43%~53%、雪莲培养物30%~40%、黄芪提取物3%~25%。
进一步的,所述复方真菌多糖由姬松茸真菌多糖和蛹虫草真菌多糖组成,其中姬松茸真菌多糖占膳食的原料质量百分比为20%~25%,蛹虫草真菌多糖占膳食的原料质量百分比为23%~28%。
进一步的,所述膳食的原料质量百分比为壳寡糖粉3%、姬松茸真菌多糖22%、蛹虫草真菌多糖25%、雪莲培养物35%、黄芪提取物15%。
一种膳食的制备方法,所述制备方法包括以下步骤:
S1、制备壳寡糖粉;首先将虾蟹壳进行脱钙、脱蛋白处理,然后再进行脱乙酰基处理后得到壳聚糖,将壳聚糖用酶降解并进行浓缩、脱色、过滤处理,最后将所得物使用低温喷雾干燥,经过质量检测后即得到壳寡糖粉;
S2、制备雪莲培养物;首先选取雪莲离体组织经脱分化形成的愈伤组织作为继代种子,然后将继代种子进行培育从而获得团块状颗粒,最后将团块状颗粒经过低温喷雾干燥得到雪莲培养物粉末;
S3、制备复方真菌多糖;该步骤分为发酵阶段和提取阶段;
发酵阶段:首先在液体培养基中放入净化水、葡萄糖、蛋白胨、酵母粉、生长因子,然后接入液体蛹虫草菌丝体、液体姬松茸菌丝体、微量亚硒酸钠并依次导入一级种子罐高温灭菌、二级种子罐、生产性发酵罐;得到复方菌丝体发酵原液;
提取阶段:首先将复方菌丝体发酵原液进行水煮并离心处理,然后在上清液中提取真菌多糖并进行低温真空浓缩从而获得浓度为15%的多糖浓缩液,将多糖浓缩液使用酒精醇沉处理清除小分子物质,最后回收乙醇并进行喷雾干燥即可获得含有有机硒的复方真菌多糖原粉;
S4、制备黄芪提取物;首先将黄芪饮片粉碎过筛得到黄芪粉末,然后使用乙醇溶液提取并过滤,过滤后的滤液进行水提取并进行离心处理,过滤后的滤渣加入纤维素酶进行酶解,酶解过后进行灭酶处理并将所得物进行第二次水提取和离心处理,最后将第一次和第二次水提取滤液合并蒸干,干燥处理后即得到黄芪多糖粉;
S5、将步骤S1、S2、S3、S4中制备的原料按其质量比称取混合即可。
与现有技术相比,本发明具有的优点和积极效果是:
本发明应用了多种活性多糖,活性多糖可以刺激免疫活性、促进淋巴细胞转化、激活T细胞和B细胞、能增强网状内皮系统吞噬肿瘤细胞的作用,并促进抗体的形成,从而在一定程度上具有抗肿瘤的活性。真菌多糖为螺旋状三维立体结构,以β-D-葡聚糖为主,具有较强的药理活性;另一方面,本发明的原料全部来自药食同源的天然植物,没有任何潜在的健康危害,可替代抗生素使用,适合各种癌症的防治;并且本发明可以作为手术放化疗二线的辅助治疗,减少癌症复发,还可以在家自己调理食用,节约大量治疗费用。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动性的前提下,还可以根据这些附图获得其他的附图。
图1为壳寡糖粉制备流程图;
图2为雪莲培养物制备流程图;
图3为复方真菌多糖制备流程图;
图4为黄芪提取物制备流程图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
如图1、2、3、4所示,本发明的复方壳寡糖调理癌症的膳食,膳食的原料质量百分比为壳寡糖粉2~4%、复方真菌多糖43%~53%、雪莲培养物30%~40%、黄芪提取物3%~25%。
所述复方真菌多糖由姬松茸真菌多糖和蛹虫草真菌多糖组成,其中姬松茸真菌多糖占膳食的原料质量百分比为20%~25%,蛹虫草真菌多糖占膳食的原料质量百分比为23%~28%。
所述姬松茸真菌多糖和蛹虫草真菌多糖均由富硒姬松茸和富硒蛹虫草制备而成。
实施例一、一种复方壳寡糖调理癌症的膳食,所述膳食的原料质量百分比为壳寡糖粉2%、姬松茸真菌多糖20%、蛹虫草真菌多糖23%、雪莲培养物30%、黄芪提取物25%。
实施例二、一种复方壳寡糖调理癌症的膳食,所述膳食的原料质量百分比为壳寡糖粉3%、姬松茸真菌多糖22%、蛹虫草真菌多糖25%、雪莲培养物35%、黄芪提取物15%。
实施例三、一种复方壳寡糖调理癌症的膳食,所述膳食的原料质量百分比为壳寡糖粉4%、姬松茸真菌多糖25%、蛹虫草真菌多糖28%、雪莲培养物40%、黄芪提取物3%。
膳食原料全部来自国家批准生产的药食同源食品和新资源食品,按规定使用量食用,没有任何潜在的健康危害。
膳食原料单方作用机理
壳寡糖(学名β-1,4-寡糖-葡萄糖胺,又叫壳聚寡糖、低聚壳聚糖)是甲壳素、壳聚糖产品的升级产品,具有壳聚糖不可比拟的优越性。壳寡糖是将壳聚糖经特殊的生物酶技术(也有使用化学降解、微波降解技术的报道)降解得到的一种聚合度在2~20之间寡糖产品。它具有壳聚糖所没有的较高溶解度,全溶于水,容易被生物体吸收的功能,其作用为壳聚糖的14倍。壳寡糖是自然界中唯一带正电荷阳离子碱性氨基低聚糖,是动物性纤维素。壳寡糖是由来源于虾蟹壳的壳聚糖降解成的带有氨基的小分子寡糖,是聚合度2-20的糖链。目前国内外学者对壳寡糖生物学效应的研究,主要集中在其抗肿瘤活性,激活巨噬细胞,T、B细胞等方面。研究表明:壳寡糖能够杜绝癌细胞的养份供应,使其分裂减少,制约癌细胞的分裂条件;减少癌细胞代谢产生的酸性废弃物,从另一方面改善癌细胞周围的酸性环境,创造一个癌细胞很难生存和分裂转移的环境条件;减少癌细胞向周围释放的各种酶(溶脂酶、水解酶、蛋白酶等);中和肿瘤周围的酸性物质,激活人体中有抗癌作用的免疫细胞,起到配合化疗、改善病症、减轻痛苦、延长生命等作用。
2013年,华中农业大学生命科学与技术学院陈红霞、梁运祥通过研究实验室自主研发制备的三种不同分子量壳寡糖(COS)对免疫系统的调节作用及对肿瘤的防治作用,进行壳寡糖增强免疫及抗肿瘤活性的研究结构表明:壳寡糖能提高正常小鼠的免疫功能,对免疫抑制小鼠的免疫功能也有很好的保护与恢复作用;不同分子量COS在体外对S180肿瘤细胞具有很强的毒性作用,在体内单独作用时也能较好地抑制肿瘤,说明壳寡糖对肿瘤具有很好的治疗辅助效果,并能有效预防肿瘤的发生。2014年,国家卫生部和国家卫生计生委发布第6号公告,批准壳寡糖为新资源食品。
雪莲培养物:天山雪莲是传统珍稀名贵的滋补药材,为菊科植物,具有独特的药性:性温、味微苦入肝、脾、肾三经,药理为温肾助阳,祛风胜湿,调经活血。现代医学研究表明,经生物提取的活性成分主要含云香甙、内酯及苷类、黄酮类、绿原酸、挥发油类等,具有软化血管、镇痛消炎、抗风湿、抗疲劳,以及清除自由基,促进人体内分泌,改善心脑血管及微循环功能和癌症的防治。雪莲培养物是从种源天山雪莲的幼茎切片在培养皿中培养,到细胞组织的形成,细胞组织培养,细胞团的收集,雪莲愈伤组织再分化,形成生芽生根的雪莲苗,使其组织或细胞增殖。细胞培养物是在无菌条件下,将离体的植物器官、组织、细胞、胚胎或原生质体培养在人工配制的培养基上进行培养。由于甄选出最佳的野生天山雪莲种子,确保植株不退化,使天山雪莲培养物有效成分与野生雪莲似度>95%,质量均衡稳定,功效成分高,具有培养的可持续性。
姬松茸(又名巴西蘑菇),原产巴西、秘鲁。它是一种夏秋生长的腐生菌。药理作用:性平,味甘;归心、肺、肝、肾经。姬松茸的抗肿瘤成分主要有核酸、外源凝集素、甾醇和脂肪酸和多糖。姬松茸的多糖体含量高达6.55g/100g,是灵芝的5倍。独特的β-(1-6)-D-葡萄糖结构直接作用于免疫力,可快速提升自然免疫细胞的生长活性。
姬松茸多糖是一种β型的葡聚糖,通过现代生物工程液态发酵,从姬松茸菌丝体中提取真菌多糖,能提高骨髓、脾脏、肝脏、血液制造及活性物质合成功能,提高红细胞内血红蛋白携氧量;提高细胞内各类生物酶的活性,提高肝脏解毒能力、抗辐射、抗化学侵害能力,并能抑制肿瘤细胞的生长,可以迅速有效的减轻化学疗法等传统治疗方法所带来的难受又危险的副作用。
蛹虫草又名北冬虫夏草,为子囊菌门,肉座目,麦角菌科、虫草属的模式种,性味甘,平。归肺、肾经,补肾益肺,止血化痰。虫草素、虫草酸和虫草多糖是野生冬虫夏草菌特有的物质,是冬虫夏草特殊功效的主要指标。而恰恰是这些指标,在人工环境优裕条件下生长的北冬虫夏草含量可以比天然条件下生长得更高。虫草素是一种广谱的抗菌素,可用于抗癌剂、抗病毒剂,临床上为辅助治疗恶性肿瘤;虫草多糖是国际医学公认的人体免疫增强剂;虫草酸(甘露醇)入肺肾二经,既能补肺阴,又能补肾阳,是唯一的一种能同时平衡、调节阴阳的中药。同时,北冬虫夏草的蛋白质、氨基酸、维生素等含量也达到或超过天然冬虫夏草的水平。因此蛹虫草具有扶正益气,提高免疫和造血能力,增强巨噬细胞的吞噬功能。蛹虫草与其他中成药配伍,对多种肿瘤、癌症的康复、预防,肿瘤、癌症放、化疗后遗症的康复产生更好的作用。
营养强化剂微量元素硒:硒是人体必需的微量元素,主要是通过蛋白质,特别是与酶蛋白结合发挥抗氧化作用,刺激抗体生成,增强吞噬细胞能力。硒做为癌细胞的杀伤剂,能减轻放、化疗的毒副作用,降低抗癌药物对肾、骨髓和肠胃的毒性,缓解患者的病痛。硒与污染食物、蓄积体内的铅、汞、镉等重金属有很强的亲和力,与其结合形成硒-金属-蛋白质复合物,直接排出体外,起到解毒和排毒作用。成年人每日食用量为60-80微克。本发明选用的微量元素硒由生物发酵工程获取。将无机硒亚硒酸钠与液体菌丝体接入液体培养基中,进行高温灭菌,无菌需氧气恒温培养而成,使化学无机硒发酵成为食用安全的生物有机硒,并与蛹虫草菌丝体融为一体。富硒虫草菌丝体粉具有强化蛹虫草的耐缺氧、抗氧化和延缓衰老的功效。
黄芪提取物:黄芪为豆科植物蒙古黄芪或膜筴黄芪的干燥根,性甘,微温。归脾,肺,肝,肾经。药理作用:升阳补气,固表止汗,利尿消肿,生津养血,脱毒排毒,收敛疮生肌。主要活性成分含多糖类、黄酮类、萜类、甾体类及皂苷类活性成分。黄芪多糖是黄芪中重要的天然有效成分,能提高人体免疫功能,增强细胞生理代谢,提高巨噬细胞活性,延缓细胞衰老,是理想的免疫增强剂。近年来多用于调节血糖和抗癌。
如图1、2、3、4所示,本发明的膳食的制备方法,包括以下步骤:
S1、制备壳寡糖粉;首先将虾蟹壳进行脱钙、脱蛋白处理,然后再进行脱乙酰基处理后得到壳聚糖,将壳聚糖用酶降解并进行浓缩、脱色、过滤处理,最后将所得物使用低温喷雾干燥,经过质量检测后即得到壳寡糖粉;
S2、制备雪莲培养物;首先选取雪莲离体组织经脱分化形成的愈伤组织作为继代种子,然后将继代种子进行培育从而获得团块状颗粒,最后将团块状颗粒经过低温喷雾干燥得到雪莲培养物粉末;
雪莲培养物主要活性物质为生物黄酮,总黄酮含量≥7%。
S3、制备复方真菌多糖;该步骤分为发酵阶段和提取阶段;
发酵阶段:首先在液体培养基中放入净化水、葡萄糖、蛋白胨、酵母粉、生长因子,然后接入液体蛹虫草菌丝体、液体姬松茸菌丝体、微量亚硒酸钠并依次导入一级种子罐高温灭菌、二级种子罐、生产性发酵罐;一级种子罐、二级种子罐、生产性发酵罐内均为无菌环境,需用氧气恒温培养;最后得到复方菌丝体发酵原液;
提取阶段:首先将复方菌丝体发酵原液进行水煮并离心处理,然后在上清液中提取真菌多糖并进行低温真空浓缩从而获得浓度为15%的多糖浓缩液,将多糖浓缩液使用酒精醇沉处理清除小分子物质,最后回收乙醇并进行喷雾干燥即可获得含有有机硒的复方真菌多糖原粉;
真菌多糖为螺旋状三维立体结构,以β-D-葡聚糖为主,具有较强的药理活性;采用液态发酵菌丝体提取的真菌多糖,可以获得含量高达25%以上,其有效成分是野生真菌的五倍以上,堪称中药的上品,并且生产的产品没有任何潜在的健康危害。
S4、制备黄芪提取物;首先将黄芪饮片粉碎过筛得到黄芪粉末,然后使用乙醇溶液提取并过滤,过滤后的滤液进行水提取并进行离心处理,过滤后的滤渣加入纤维素酶进行酶解,酶解过后进行灭酶处理并将所得物进行第二次水提取和离心处理,最后将第一次和第二次水提取滤液合并蒸干,干燥处理后即得到黄芪多糖粉;
S5、将步骤S1、S2、S3、S4中制备的原料按其质量比称取混合即可。
膳食的原料不用传统的粉碎和熬制方法,全部采用现代中药发酵提取技术,降解原料中的有害物质,高效获取中药的活性成分并且应用了多种活性多糖,活性多糖可以刺激免疫活性,能增强网状内皮系统吞噬肿瘤细胞的作用,促进淋巴细胞转化,激活T细胞和B细胞,并促进抗体的形成,从而在一定程度上具有抗肿瘤的活性。
Claims (4)
1.一种复方壳寡糖调理癌症的膳食,其特征在于:所述膳食的原料质量百分比为壳寡糖粉2~4%、复方真菌多糖43%~53%、雪莲培养物30%~40%、黄芪提取物3%~25%。
2.如权利要求1所述的复方壳寡糖调理癌症的膳食,其特征在于:所述复方真菌多糖由姬松茸真菌多糖和蛹虫草真菌多糖组成,其中姬松茸真菌多糖占膳食的原料质量百分比为20%~25%,蛹虫草真菌多糖占膳食的原料质量百分比为23%~28%。
3.如权利要求2所述的复方壳寡糖调理癌症的膳食,其特征在于:所述膳食的原料质量百分比为壳寡糖粉3%、姬松茸真菌多糖22%、蛹虫草真菌多糖25%、雪莲培养物35%、黄芪提取物15%。
4.如权利要求2或3任一所述膳食的制备方法,其特征在于:所述制备方法包括以下步骤:
S1、制备壳寡糖粉;首先将虾蟹壳进行脱钙、脱蛋白处理,然后再进行脱乙酰基处理后得到壳聚糖,将壳聚糖用酶降解并进行浓缩、脱色、过滤处理,最后将所得物使用低温喷雾干燥,经过质量检测后即得到壳寡糖粉;
S2、制备雪莲培养物;首先选取雪莲离体组织经脱分化形成的愈伤组织作为继代种子,然后将继代种子进行培育从而获得团块状颗粒,最后将团块状颗粒经过低温喷雾干燥得到雪莲培养物粉末;
S3、制备复方真菌多糖;该步骤分为发酵阶段和提取阶段;
发酵阶段:首先在液体培养基中放入净化水、葡萄糖、蛋白胨、酵母粉、生长因子,然后接入液体蛹虫草菌丝体、液体姬松茸菌丝体、微量亚硒酸钠并依次导入一级种子罐高温灭菌、二级种子罐、生产性发酵罐;得到复方菌丝体发酵原液;
提取阶段:首先将复方菌丝体发酵原液进行水煮并离心处理,然后在上清液中提取真菌多糖并进行低温真空浓缩从而获得浓度为15%的多糖浓缩液,将多糖浓缩液使用酒精醇沉处理清除小分子物质,最后回收乙醇并进行喷雾干燥即可获得含有有机硒的复方真菌多糖原粉;
S4、制备黄芪提取物;首先将黄芪饮片粉碎过筛得到黄芪粉末,然后使用乙醇溶液提取并过滤,过滤后的滤液进行水提取并进行离心处理,过滤后的滤渣加入纤维素酶进行酶解,酶解过后进行灭酶处理并将所得物进行第二次水提取和离心处理,最后将第一次和第二次水提取滤液合并蒸干,干燥处理后即得到黄芪多糖粉;
S5、将步骤S1、S2、S3、S4中制备的原料按其质量比称取混合均匀即可。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810341127.8A CN108576792A (zh) | 2018-04-17 | 2018-04-17 | 一种复方壳寡糖调理癌症的膳食及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810341127.8A CN108576792A (zh) | 2018-04-17 | 2018-04-17 | 一种复方壳寡糖调理癌症的膳食及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108576792A true CN108576792A (zh) | 2018-09-28 |
Family
ID=63622765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810341127.8A Pending CN108576792A (zh) | 2018-04-17 | 2018-04-17 | 一种复方壳寡糖调理癌症的膳食及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108576792A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115364138A (zh) * | 2022-09-19 | 2022-11-22 | 博斯创想(上海)医疗科技有限公司 | 一种用于改善化疗副作用的复合菌液及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102258563A (zh) * | 2010-05-28 | 2011-11-30 | 浦元清 | 一种抗癌药物组合物和一种中药组合物 |
CN103340340A (zh) * | 2013-06-07 | 2013-10-09 | 青岛银龄美海洋生物科技有限公司 | 提高免疫力的保健食品 |
CN107007646A (zh) * | 2017-03-14 | 2017-08-04 | 郑笃达 | 一种辅助防治癌症的营养复合物 |
-
2018
- 2018-04-17 CN CN201810341127.8A patent/CN108576792A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102258563A (zh) * | 2010-05-28 | 2011-11-30 | 浦元清 | 一种抗癌药物组合物和一种中药组合物 |
CN103340340A (zh) * | 2013-06-07 | 2013-10-09 | 青岛银龄美海洋生物科技有限公司 | 提高免疫力的保健食品 |
CN107007646A (zh) * | 2017-03-14 | 2017-08-04 | 郑笃达 | 一种辅助防治癌症的营养复合物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115364138A (zh) * | 2022-09-19 | 2022-11-22 | 博斯创想(上海)医疗科技有限公司 | 一种用于改善化疗副作用的复合菌液及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101624570B (zh) | 中药培养养殖肉灵芝方法及养殖肉灵芝保健品的制备方法 | |
CN104479946A (zh) | 黄秋葵、菌、藻植物组合物制作营养露酒的方法 | |
CN1676036A (zh) | 灵芝金刚根保健食品及其制备方法 | |
CN103877122A (zh) | 中药阿胶原料的生产方法及其产品 | |
CN105495560A (zh) | 一种复合植物多糖与菌类多糖的营养食品 | |
CN105384562A (zh) | 一种袖珍菇培养基 | |
CN107432911B (zh) | 一种养生补肾的人参含片及其制备方法 | |
CN104940241B (zh) | 一种防治妇女更年期综合征的硒虫草复方制剂 | |
WO1995018626A1 (fr) | Medicament tonique a base de basidiomycetes, d'algues et d'herbes officinales chinoises, et son procede de preparation | |
CN108576792A (zh) | 一种复方壳寡糖调理癌症的膳食及其制备方法 | |
CN104906140A (zh) | 一种阿胶及其制备方法与相关设备 | |
CN104430720A (zh) | 黄秋葵、菌、藻植物组合物制作功能性饼干的方法 | |
CN107893035A (zh) | 一种猴头菌的培养基、黄精生物转化菌丝体、黄精生物转化菌丝体的提取物及其用途 | |
CN112043730A (zh) | 一种防治动物疫病的中药生物制剂 | |
CN104432305A (zh) | 一种食疗功能饮料及其制备方法 | |
CN108902731A (zh) | 一种健脾养胃、促进儿童智力发育及身体成长的面条及其制备方法 | |
CN104382007B (zh) | 一种功能性胶囊及其制备方法 | |
CN106421154A (zh) | 一种具有修复细胞、抗衰老、抗癌功能的沉香中药组合物、中药制剂及其制备方法 | |
CN104450374B (zh) | 一种黄秋葵、菌、藻组合物保健酒及其制备方法 | |
CN109315739A (zh) | 一种枸杞蜂花粉抗肿瘤保健食品及其制备方法 | |
CN104430719A (zh) | 黄秋葵、菌、藻植物组合物制作保康酥的方法 | |
CN103416635B (zh) | 一种禽类养殖中草药饲料改良剂及其制备工艺 | |
CN117084404A (zh) | 一种预防未病的组合物及其制备方法 | |
CN108478700A (zh) | 一种提高亚健康人群免疫力的组合物及其制备方法与应用 | |
CN113303399A (zh) | 一种植物复方提取物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180928 |